Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

RARE Ultragenyx Pharmaceutical Inc.
$14.50 12.58% +1.62
Notify me if price changes either direction
Interactive Brokers Logotype

Buy RARE stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 1.4B
Enterprise value 2.2B
Trailing PE -2.4871355060034
Forward PE 63.82557
PEG Ratio 0.10777587192682
Enterprise to EBITDA -4.735
Enterprise to revenue 3.071
Price to book MRQ -5.2026408450704
Price to sales TTM 1.7710246

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-06-30
Revenue (TTM) 717.0M
EBITDA -465000000
Diluted EPS TTM -5.83
Total Cash (MRQ) 292.0M
Current ratio (MRQ) 1.726
Operating Cash Flow (TTM) -485000000

RARE trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent RARE News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.